Radiofrequency Ablation as a Method of Local Tumor Control: Current Role in Oncology

An organ-preserving approach and minimizing invasiveness are among the leading trends in modern oncology, where radiofrequency ablation (RFA) holds a prominent place. For a practicing physician, this is primarily an effective way to radically and safely affect tumor foci in clinical situations where open resection is impossible or too risky for the patient.

At the same time, remember: RFA is not a universal replacement for surgery or chemotherapy. It is an independent, high-precision method for situations requiring effective local tumor control.

RFA: What kind of method is it

RFA is a minimally invasive technique for locally destroying tumor tissue with heat. A high-frequency current (350–500 kHz) is applied to the focus through a puncture needle-electrode under ultrasound or CT guidance. This causes ion agitation in the tissues, heats the area to 60–100 °C, and kills tumor cells through coagulation necrosis.

Today, Ukraine has access to advanced equipment for the most effective RFA procedures. In particular, the Cor-Medical team supplies the innovative Cool-tip™ E Series equipment from the authoritative American corporation Medtronic. This device has already received excellent feedback from Ukrainian and international doctors for its reliability, safety, and high precision.

What place does RFA occupy among local treatment methods

Among local treatment methods, RFA falls between surgical resection and active surveillance. Compared to open surgeries, RFA minimizes blood loss and preserves functioning organ tissue, and among other ablation methods (cryo- and microwave), it is the most studied and standardized in international protocols.

How radiofrequency tumor ablation works

The procedure relies on creating a strictly controlled heating zone. Destruction efficiency depends on the achieved temperature, exposure duration, tissue density, and local blood flow characteristics. Therefore, doctors approach RFA equipment selection with the utmost care.

The Cool-tip ablator offers unique advantages critical to a doctor's work: it includes an additional temperature sensor for real-time process monitoring, provides high-quality visualization, and features an intuitive interface. Thanks to a high-power 200 W generator and effective water cooling of the electrode, the procedure takes only 12–15 minutes.

The main goal is to create a stable zone of necrosis. It must completely overlap the tumor and encompass 5–10 mm of surrounding healthy tissue (safety margin), preventing viable malignant cells from remaining. Thanks to their innovative shape, Cool-tip electrodes easily penetrate bulky formations and promote the formation of a perfectly spherical coagulate, ensuring complete coverage of the focus.

Why tumor size and localization matter

The optimal target for RFA is lesions up to 3–4 cm in diameter. With larger lesions, it is harder to achieve uniform heating. In addition, nearby large blood vessels create a heat-sink effect that cools the tumor and reduces procedure efficiency, while proximity to hollow organs requires protective techniques (e.g., hydrodissection).

Interventional oncology and local tumor ablation

Modern interventional oncology combines high-precision visualization and minimally invasive access, allowing for targeted tumor destruction without significant incisions. In this context, local tumor ablation becomes an indispensable tool.

What tasks can local tumor ablation solve:

• Radical removal of early tumors in patients with high surgical or anesthetic risk.
• Control of oligometastases (in particular, RFA is effective for liver, lung, kidney, and bone tumors).
• Cytoreduction to decrease tumor burden.
• Palliative relief of pain syndrome (in particular with bone metastases).

RFA as part of multimodal treatment

RFA is rarely used in isolation: it is successfully combined with chemo-, targeted, and immunotherapy, and the sequence of stages must be approved by a multidisciplinary oncology council.

Patient selection for radiofrequency ablation

Careful selection is the main factor in relapse-free survival and patient safety.

What tumor characteristics are considered:

• Number of foci (usually up to 3–5).
• Exact linear dimensions in three projections.
• Anatomical location and distance to vessels/ducts.
• Safety of access for electrode insertion.

Remember that a nodule on a scan is not an automatic indication for RFA. Decisive factors include overall performance status (ECOG), functional organ reserve (e.g., Child-Pugh for the liver), tumor growth rate, and response to prior systemic treatment.

Рисунок 3

Local tumor control: How the result of RFA is evaluated

Treatment quality is evaluated based on clear radiological criteria of complete destruction, not just on the technical act of performing the procedure.

In 1–3 months, contrast-enhanced CT or MRI is performed (according to mRECIST criteria). A successful ablation looks like a clearly defined avascular zone without contrast accumulation.

Preserved blood flow in the focus indicates residual tumor tissue, and new contrast areas along the periphery indicate relapse, which requires repeat ablation or a change in treatment tactics.

Advantages and limitations of RFA

The method has a clear balance between clinical benefit and anatomical-technical limits.

What are the potential advantages of the method:

• Low trauma and short hospital stay (1–3 days).
• Possibility of execution under local anesthesia or sedation.
• Maximum preservation of functional organ parenchyma.
• Possibility of repeated application in case of new foci.
• High safety standards (additional sensors, water cooling, etc.).

What factors may limit the application:

• Tumor size over 4–5 cm.
• Diffuse organ involvement.
• Uncorrected coagulopathy.
• Risk of thermal damage to adjacent major vessels or intestines.

RFA in a comprehensive strategy for treating an oncological patient

RFA can significantly improve prognosis and quality of life for patients with oligometastatic disease.

The Cool-tip system is used effectively to ablate liver, lung, kidney, and bone tumors. In the clinical case below, an abdominal surgeon and surgical oncologist at the O.O. Shalimov National Scientific Center of Surgery and Transplantology of the National Academy of Medical Sciences of Ukraine, Anatoliy Skums, shares his direct experience and detailed feedback on treating colorectal cancer with liver metastases, demonstrating the high results and accuracy of the device.

Targeted destruction of individual nodes allows achieving long-term remission, slowing progression, and even giving the patient a safe "chemotherapy holiday" without disabling open surgeries.

The decision on RFA is the result of a multidisciplinary approach

The clinical success of RFA is based on the joint work of an oncologist, surgeon, and interventional radiologist. Understanding the method allows timely offering the patient a minimally traumatic solution when open surgery carries excessive risks.

However, the value of RFA in modern oncology depends not on the technology itself, but on competent patient selection, technical feasibility, and a clearly defined goal of local tumor control.

To get an individual consultation on the use of the Cool-tip radiofrequency ablation system, please contact Cor-Medical specialists. Call 0800 402 400 or email a request to info@cor-medical.com.